Florian Ringel1, Haiko Pape1, Michael Sabel1, Dietmar Krex1, Hans Christoph Bock1, Martin Misch1, Astrid Weyerbrock1, Thomas Westermaier1, Christian Senft1, Philippe Schucht1, Bernhard Meyer1, Matthias Simon1. 1. Department of Neurosurgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany (F.R., H.P., B.M.); Department of Neurosurgery, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (M.S.); Department of Neurosurgery, Universitätsklinikum Carl Gustav Carus, Dresden, Germany (D.K.); Department of Neurosurgery, Universitätsmedizin Göttingen, , Göttingen, Germany (H.C.B.); Department of Neurosurgery, Charité Universitätsmedizin, Berlin, Germany (M.M.); Department of Neurosurgery, Universitätsklinikum Freiburg, Freiburg, Germany (A.W.); Department of Neurosurgery, Universitätsklinikum Würzburg, Würzburg, Germany (T.W.); Department of Neurosurgery, Goethe Universität Frankfurt, Frankfurt, Germany (C.S.); Department of Neurosurgery, Inselspital, Universitätsklinikum Bern, Bern, Switzerland (P.S.); Department of Neurosurgery, Universitätskliniken Bonn, Rheinische Friedrich Wilhelms Universität, Bonn, Germany (M.S.).
Abstract
BACKGROUND: While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recurrent glioblastomas on patient survival. METHODS: In a multicenter retrospective-design study, patients with primary glioblastomas undergoing repeat resections for recurrent tumors were evaluated for factors affecting survival. Age, Karnofsky performance status (KPS), extent of resection (EOR), tumor location, and complications were assessed. RESULTS: Five hundred and three patients (initially diagnosed between 2006 and 2010) undergoing resections for recurrent glioblastoma at 20 institutions were included in the study. The patients' median overall survival after initial diagnosis was 25.0 months and 11.9 months after first re-resection. The following parameters were found to influence survival significantly after first re-resection: preoperative and postoperative KPS, EOR of first re-resection, and chemotherapy after first re-resection. The rate of permanent new deficits after first re-resection was 8%. CONCLUSION: The present study supports the view that surgical resections of recurrent glioblastomas may help to prolong patient survival at an acceptable complication rate.
BACKGROUND: While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recurrent glioblastomas on patient survival. METHODS: In a multicenter retrospective-design study, patients with primary glioblastomas undergoing repeat resections for recurrent tumors were evaluated for factors affecting survival. Age, Karnofsky performance status (KPS), extent of resection (EOR), tumor location, and complications were assessed. RESULTS: Five hundred and three patients (initially diagnosed between 2006 and 2010) undergoing resections for recurrent glioblastoma at 20 institutions were included in the study. The patients' median overall survival after initial diagnosis was 25.0 months and 11.9 months after first re-resection. The following parameters were found to influence survival significantly after first re-resection: preoperative and postoperative KPS, EOR of first re-resection, and chemotherapy after first re-resection. The rate of permanent new deficits after first re-resection was 8%. CONCLUSION: The present study supports the view that surgical resections of recurrent glioblastomas may help to prolong patient survival at an acceptable complication rate.
Authors: John F de Groot; Kathleen R Lamborn; Susan M Chang; Mark R Gilbert; Timothy F Cloughesy; Kenneth Aldape; Jun Yao; Edward F Jackson; Frank Lieberman; H Ian Robins; Minesh P Mehta; Andrew B Lassman; Lisa M Deangelis; W K Alfred Yung; Alice Chen; Michael D Prados; Patrick Y Wen Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya Journal: J Neurosurg Date: 2001-08 Impact factor: 5.115
Authors: Jason M Hoover; Macaulay Nwojo; Ross Puffer; Jay Mandrekar; Fredric B Meyer; Ian F Parney Journal: J Neurosurg Date: 2013-03-15 Impact factor: 5.115
Authors: B Young; E H Oldfield; W R Markesbery; D Haack; P A Tibbs; P McCombs; H W Chin; Y Maruyama; W F Meacham Journal: J Neurosurg Date: 1981-12 Impact factor: 5.115
Authors: Kaisorn L Chaichana; Patricia Zadnik; Jon D Weingart; Alessandro Olivi; Gary L Gallia; Jaishri Blakeley; Michael Lim; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2012-10-19 Impact factor: 5.115
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Debra A Goldman; Koos Hovinga; Anne S Reiner; Yoshua Esquenazi; Viviane Tabar; Katherine S Panageas Journal: J Neurosurg Date: 2018-11-01 Impact factor: 5.115
Authors: Ali S Haider; Martin van den Bent; Patrick Y Wen; Michael A Vogelbaum; Susan Chang; Peter D Canoll; Craig M Horbinski; Jason T Huse Journal: Neuro Oncol Date: 2020-04-15 Impact factor: 12.300
Authors: Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2016-04-19 Impact factor: 4.130